BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33187685)

  • 1. YJ5 as an immunohistochemical marker of osteogenic lineage.
    Chua K; Virshup DM; Odono EG; Chang KTE; Tan NJH; Hue SS; Sim AYL; Lee VKM
    Pathology; 2021 Feb; 53(2):229-238. PubMed ID: 33187685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours.
    Conner JR; Hornick JL
    Histopathology; 2013 Jul; 63(1):36-49. PubMed ID: 23701429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
    Davis JL; Horvai AE
    Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
    Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
    Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
    Machado I; Navarro S; Picci P; Llombart-Bosch A
    Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p63 expression in giant cell-containing lesions of bone and soft tissue.
    de la Roza G
    Arch Pathol Lab Med; 2011 Jun; 135(6):776-9. PubMed ID: 21631272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
    Dohi O; Ohtani H; Hatori M; Sato E; Hosaka M; Nagura H; Itoi E; Kokubun S
    Histopathology; 2009 Oct; 55(4):432-40. PubMed ID: 19817894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocytochemical identification of osteogenic bone tumors by osteonectin antibodies.
    Jundt G; Schulz A; Berghäuser KH; Fisher LW; Gehron-Robey P; Termine JD
    Virchows Arch A Pathol Anat Histopathol; 1989; 414(4):345-53. PubMed ID: 2496522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma].
    Chen CY; Zhang HZ; Jiang ZM; Zhou J; Chen J; Liu L
    Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):387-92. PubMed ID: 27256046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
    Shooshtarizadeh T; Rahimi M; Movahedinia S
    Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of SATB2 in primary cutaneous sarcomatoid neoplasms: a potential diagnostic pitfall.
    Szczepanski JM; Siddiqui J; Patel RM; Harms PW; Hrycaj SM; Chan MP
    Pathology; 2023 Apr; 55(3):350-354. PubMed ID: 36732203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
    Ud Din N; Umer M; Park YK
    Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
    [No Abstract]   [Full Text] [Related]  

  • 13. Sclerostin expression in bone tumours and tumour-like lesions.
    Inagaki Y; Hookway ES; Kashima TG; Munemoto M; Tanaka Y; Hassan AB; Oppermann U; Athanasou NA
    Histopathology; 2016 Sep; 69(3):470-8. PubMed ID: 26896083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulators of skeletal development: a cluster analysis of 206 bone tumors reveals diagnostically useful markers.
    Horvai AE; Roy R; Borys D; O'Donnell RJ
    Mod Pathol; 2012 Nov; 25(11):1452-61. PubMed ID: 22766796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics.
    Jiang L; Liu J; Wei Q; Wang Y
    Diagn Pathol; 2020 Nov; 15(1):135. PubMed ID: 33176814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series.
    Wojcik JB; Bellizzi AM; Dal Cin P; Bredella MA; Fletcher CD; Hornicek FJ; Deshpande V; Hornick JL; Nielsen GP
    Am J Surg Pathol; 2014 Nov; 38(11):1538-44. PubMed ID: 24921641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dentine matrix protein 1 (DMP-1) is a marker of bone formation and mineralisation in soft tissue tumours.
    Inagaki Y; Kashima TG; Hookway ES; Tanaka Y; Hassan AB; Oppermann U; Athanasou NA
    Virchows Arch; 2015 Apr; 466(4):445-52. PubMed ID: 25630512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
    Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
    Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours: comment on Conner et al. (2013).
    Creytens D; Ferdinande L
    Histopathology; 2015 Aug; 67(2):272-3. PubMed ID: 25469978
    [No Abstract]   [Full Text] [Related]  

  • 20. ERG expression in chondrogenic bone and soft tissue tumours.
    Shon W; Folpe AL; Fritchie KJ
    J Clin Pathol; 2015 Feb; 68(2):125-9. PubMed ID: 25378537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.